Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TXG | INST-CLUSTER | neutral | 2/10 | Three small asset managers added to their TXG positions in Q3 2026, with aggregate current holdings of $3.3M and net buy | Oct 23, 2026 |
| DNA | CLUSTER | neutral | 2/10 | Two insiders at Ginkgo Bioworks sold a combined $198K in open-market sales on October 19, 2026. The selling is dominated | Oct 21, 2026 |
| CRSP | CLUSTER | bearish | 5/10 | Three insiders at CRISPR Therapeutics sold a total of ~$3.15M in open-market sales within a week, including the CEO ($2. | Oct 20, 2026 |
| ILMN | INST-CLUSTER | bullish | 4/10 | A strong institutional cluster formed in ILMN during Q3 2026, with 5 active managers accumulating $488.9M net in new pos | Oct 20, 2026 |
| CRSP | 8-K | neutral | 3/10 | CRISPR Therapeutics announced the promotion of Andrew J. Silver from SVP, Finance to CFO, effective October 19, 2026, re | Oct 19, 2026 |
| DNA | 144 | neutral | 2/10 | Steven P. Coen, an officer of Ginkgo Bioworks, filed a Form 144 notice of intent to sell 766 Class A shares valued at ap | Oct 19, 2026 |
| BNGO | SC 13G | neutral | 4/10 | Orin Hirschman and affiliated entities (AIGH Capital Management LLC, AIGH Investment Partners LLC) filed a new Schedule | Oct 19, 2026 |
| PACB | PRESS-RELEASE | neutral | 4/10 | PacBio announced a multi-year strategic collaboration with Verily Health to integrate its HiFi long-read sequencing with | Oct 19, 2026 |
| CRSP | CLUSTER | neutral | 3/10 | Three CRSP insiders, including the CEO and a director, sold a combined ~$973K in open-market sales over a two-day window | Oct 16, 2026 |
| CRSP | CLUSTER | bearish | 4/10 | Three CRISPR Therapeutics insiders, including the CEO and General Counsel, sold a total of ~$973K in open-market sales o | Oct 16, 2026 |
| BEAM | 144 | neutral | 3/10 | John M. Evans, an officer and director of Beam Therapeutics, filed a Form 144 notice to sell 25,000 common shares with a | Oct 16, 2026 |
| CRSP | CLUSTER | neutral | 3/10 | CEO Samarth Kulkarni and General Counsel James Kasinger sold a combined $253K in CRSP stock on October 14, 2026, at $49. | Oct 15, 2026 |
| RXRX | 424B5 | bearish | 6/10 | Recursion Pharmaceuticals is offering 61,540,000 shares of Class A common stock at $3.25 per share, raising approximatel | Oct 15, 2026 |
| RXRX | 8-K | mixed | 6/10 | Recursion Pharmaceuticals filed an 8-K announcing a $200M oversubscribed follow-on offering of 61.54M shares at $3.25/sh | Oct 15, 2026 |
| RXRX | PRESS-RELEASE | mixed | 5/10 | Recursion Pharmaceuticals announced that Sanofi has optioned the first development candidate from their multi-program co | Oct 15, 2026 |
| RXRX | PRESS-RELEASE | bearish | 6/10 | Recursion Pharmaceuticals priced a $200 million underwritten public offering of 61.54 million shares at $3.25 per share, | Oct 15, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion Pharmaceuticals announced a $200 million underwritten common stock offering alongside positive clinical data u | Oct 15, 2026 |
| RXRX | 424B5 | bearish | 6/10 | Recursion Pharmaceuticals is filing a preliminary prospectus supplement for a $200 million underwritten public offering | Oct 15, 2026 |
| CRSP | 144 | neutral | 2/10 | Director George Simeon filed a Form 144 notice to sell 14,514 shares of CRISPR Therapeutics common stock, with an estima | Oct 14, 2026 |
| ILMN | 8-K | neutral | 3/10 | Illumina established a $1.0 billion unsecured commercial paper program on October 8, 2026, with three dealers and a nati | Oct 13, 2026 |
| TWST | CLUSTER | bearish | 6/10 | Six Twist Bioscience insiders, including the CEO, President/COO, and CFO, sold a combined $17.86M in shares over a one-w | Oct 12, 2026 |
| ILMN | INST-CLUSTER | mixed | 4/10 | A mixed institutional cluster for Illumina in Q2 2026 shows 54 buyers accumulating $1.02B net (dominated by Fidelity's $ | Oct 12, 2026 |
| TWST | 144 | neutral | 2/10 | Twist Bioscience officer Adam Laponis filed a Form 144 notice of intent to sell 2,462 shares of common stock, valued at | Oct 9, 2026 |
| EDIT | 8-K | bullish | 6/10 | Editas Medicine announced regulatory approval in Australia to initiate the Phase 1/2 Strive clinical trial of EDIT-401, | Oct 8, 2026 |
| TXG | SC 13G/A | neutral | 2/10 | ARK Investment Management LLC and Catherine D. Wood filed Amendment No. 4 to their Schedule 13G, reporting a 5.22% passi | Oct 7, 2026 |
| ILMN | SC 13G | neutral | 4/10 | FMR LLC (Fidelity) filed a Schedule 13G disclosing a 10.7% passive stake in Illumina as of September 30, 2026, represent | Oct 7, 2026 |
| CRSP | 144 | neutral | 2/10 | James R. Kasinger, an officer of CRISPR Therapeutics AG, filed a Form 144 on October 6, 2026, indicating intent to sell | Oct 6, 2026 |
| PACB | 144 | bearish | 5/10 | Director James R. Gibson II filed a Form 144 notice of intent to sell up to 661,815 shares of Pacific Biosciences of Cal | Oct 6, 2026 |
| RXRX | 144 | neutral | 2/10 | Director Blake Borgeson filed a Form 144 notice of intent to sell 50,000 Class A shares of Recursion Pharmaceuticals, wi | Oct 6, 2026 |
| RXRX | 144 | neutral | 3/10 | Director Robert Hershberg filed a Form 144 notice to sell 25,000 Class A shares of Recursion Pharmaceuticals, with an es | Oct 6, 2026 |
Page 1 of 7 Next »